A Narrative Review on Fanconi Anemia: Genetic and Diagnostic Considerations

Preksha Sharma¹  Neha Sharma²  Dhruva Sharma³

¹Department of Anatomy, SMS Medical College and Attached Hospitals, Jaipur, Rajasthan, India
²Department of Pharmacology, SMS Medical College and Attached Hospitals, Jaipur, Rajasthan, India
³Department of Cardiothoracic and Vascular Surgery, SMS Medical College and Attached Hospitals, Jaipur, Rajasthan, India

Address for correspondence Preksha Sharma, MBBS, MS, Department of Anatomy, SMS Medical College and Attached Hospitals, JLN Marg, Jaipur 302001, Rajasthan, India (e-mail: sharmadrpreksha@gmail.com).

Glob Med Genet 2022;9:237–241.

Abstract

Fanconi anemia (FA) is an autosomal recessive disorder, both genetically and phenotypically. It is characterized by chromosomal instability, progressive bone marrow failure, susceptibility to cancer, and various other congenital abnormalities. It involves all the three cell lines of blood. So far, biallelic mutations in 21 genes and one x-linked gene have been detected and found to be associated with FA phenotype. Signs and symptoms start setting in by the age of 4 to 7 years, mainly hematological symptoms. This includes pancytopenia, that is, a reduction in the number of white blood cells (WBCs), red blood cells (RBCs), and platelets. Therefore, the main criteria for diagnosis of FA include skeletal malformations, pancytopenia, hyperpigmentation, short stature, urogenital abnormalities, central nervous system, auditory, renal, ocular, and familial occurrence. Patients showing signs and symptoms of FA should be thoroughly evaluated. A complete blood count will reveal a reduced number of RBC, WBC, and platelets, that is, pancytopenia. Chromosomal breakage study/stress cytogenetics should be done in patients with severe pancytopenia. Momentousness timely diagnosis of current disease, prenatal diagnosis, and genetic counseling should be emphasized.

Keywords
► Fanconi anemia
► pancytopenia
► acute myeloid leukemia
► stress cytogenetics

Introduction

Fanconi anemia (FA) is an autosomal recessive disorder, both genetically and phenotypically.¹ It comes under the category of rare disease with a prevalence of 1 in 160,000 (www.orpha.net), but this is the most commonly inherited bone marrow failure syndrome.² Ashkenazi Jews, Afrikaners, and Spanish Gypsies have reported a higher incidence of FA.³ It is characterized by chromosomal instability, progressive bone marrow failure, susceptibility to cancer, and various other congenital abnormalities.⁴ It involves all the three cell lines of blood. In around 2% of the cases, it is inherited in an X-linked recessive manner. The mutations can be homozygous as well as heterozygous.⁴,⁵ Out of all the phenotypes that have been reported to be associated with FA, hypersensitivity to DNA crosslinking agents like mitomycin C (MMC) and diepoxybutane (DEB) remains the most persistent one.⁶

Genetics

It is an autosomal recessive disorder except when there is the mutation of FANCB, which is located on the X chromosome, and inherited in an autosomal dominant manner when there is the mutation of FANCR.⁷,⁸ A DNA sequence can be reckoned as an FA gene when an inactivating mutation is associated with chromosomal breakage when subjected to DNA cross-linking agents (such as MMC and DEB) in minimum one patient, and

© 2022. The Author(s).
This is an open access article published by Thieme under the terms of the Creative Commons Attribution License, permitting unrestricted use, distribution, and reproduction so long as the original work is properly cited. (https://creativecommons.org/licenses/by/4.0/)
Georg Thieme Verlag KG, Rüdigerstraße 14, 70469 Stuttgart, Germany
the breakage gets corrected by complementation with the wild-type version of the mutant alleles.\textsuperscript{9} So far biallelic mutations in 21 genes and one x-linked gene have been detected and found to be associated with FA phenotype.\textsuperscript{9,10} The genes that commensurate with different complementation groups in FA are involved in the FA/BRCA DNA damage repair pathway and play an important role in generating a response to DNA alkylating agents.\textsuperscript{11} FANCA, FANCC, and FANCG have been found to be common FA complementation groups.\textsuperscript{12} In around 60 to 70% patients diagnosed with FA, FANCA gene mutation predominates. These mutations may be insertion or deletion which may lead to premature termination or large deletions and null mutations.\textsuperscript{13}

**Multimer Complex by Fanconi Anemia Proteins**

It is suggested that FA genes interact by the way of a biochemical pathway or multimer complex. Based on various findings which propound that FANCA and FANCC together form a complex and migrate to the nucleus, some investigators suggest that FANCC and FANCA do not interact with each other as they are in different compartments in the cell. Nuclear assembly of the protein complex, as well as binding, gets disrupted in FA-A, FA-C, FA-B, -E, -F, and -G cells. On the contrary, these remain intact in FA-D cells.\textsuperscript{13–18} FANCA and FANCC form a complex and translocate to the nuclei, where they are involved in nuclear processes, such as DNA replication, DNA repair, and transcription. However, FANCD is a downstream gene and functions independently. Many studies concluded that FANCA, FANCC, and FANCG protein complexes are present in both nuclei and cytoplasm.

**Spindle Assembly Checkpoints**

Spindle-assembly checkpoint was first discovered in yeast *Saccharomyces cerevisiae*. It is a signaling network which promotes tumor suppression by segregating high fidelity chromosomes during mitosis. This further helps in preventing aneuploidy.\textsuperscript{19–22} The genes which have been identified are MAD (mitotic-arrest deficient) genes MAD1, MAD2, and MAD3 (BUBR1 in humans) and the BUB (budding uninhibited by benzimidazole) gene BUB1.\textsuperscript{23,24} All these genes are found to be actively involved in a pathway which impedes the premature separation of sister chromatid, and this pathway is active in prometaphase.\textsuperscript{23}

**Signs and Symptoms Associated with Fanconi Anemia**

Signs and symptoms start setting in by the age of 4 to 7 years, mainly hematological symptoms. This includes pancytopenia, that is, a reduction in the number of white blood cells (WBCs), red blood cells (RBCs), and platelets. Therefore, the main criteria for diagnosis of FA include skeletal malformations, pancytopenia, hyperpigmentation, short stature, urogenital abnormalities, central nervous system, auditory, renal, ocular, and familial occurrence. It has been observed that the incidence of congenital abnormalities in probands is more than in their affected sibling. Proband is a person who is first affected in the family and serves as the starting point for the genetic study in that family.\textsuperscript{24} Chest pain, shortness of breath, dizziness, and fatigue are commonly present in FA. Patients give the history of petechiae, epistaxis, and unstoppable bleeding from a wound site that is due to thrombocytopenia. Flu-like illness and fever are frequently encountered and there is an increased risk of infection due to leukopenia.

Around 75% of FA patients present with birth defects. In approximately 50% of the cases, the child may present with short stature and café-au-lait spots (area of hyperpigmentation found on skin).\textsuperscript{25} Other abnormalities of the extremity associated with FA are hypoplastic or absent radii, hypoplastic thumb (radial ray defect), and dysplastic ulna in the upper extremity, whereas hip dislocation, short toes, club foot, polydactyly, and thigh osteoma are seen in the lower extremity. Other skeletal abnormalities include frontal bossing, microcephaly and hydrocephaly, spina bifida, webbed and short neck, micrognathia, scoliosis, extra vertebrae, and abnormal ribs. Tracheoesophageal fistula, imperforate anus, umbilical hernia, Meckel’s diverticulum are some of the gastrointestinal abnormalities encountered in FA. Gastrointestinal abnormalities are less common.

Physical manifestations of pancytopenia are bruising, petechiae, pallor, and coldness of hands and feet. FA patients develop bone marrow aplasia and pancytopenia between 2 and 13 years of age. Some patients may present with these manifestations later in life, that is, during adolescence or even after that. Most of the FA patients eventually develop acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS).\textsuperscript{26–28} Therefore, regular follow-up of these patients is required. These patients are at a very high risk of developing hepatocellular carcinoma as well as hepatic adenoma.\textsuperscript{29,30} In an analysis conducted by the European Fanconi Anemia Research Group, it was found that 8 and 9% of the patients diagnosed with FA developed MDS and AML, respectively. In some of the patients, the first hematological abnormality to be detected was AML/MDS and few patients presented with AML/MDS post bone marrow aplasia. Significantly younger patients presented in the former group as compared with the latter. Deletions of 5q, 7q, 20q, trisomy 8, monosomy 7, and chromosome abnormalities are frequently occurring cytogenetic abnormalities in FA patients with AML/MDS.\textsuperscript{28}

Growth abnormality which includes short stature is often associated with hormone deficiencies such as insulin resistance or deficiency, growth hormone deficiency, and pituitary hypofunction and hypogonadism. Hypogonadism is encountered in both sexes. There may be an underlying hypothalamic–pituitary dysfunction which leads to abnormal growth hormone secretion. Hence, endocrine evaluation for all children should be advised at an early age, in an order to improve quality of life and final height, by correcting growth and thyroid hormone deficiency.\textsuperscript{1}

**Differential Diagnosis**

A large number of diseases resemble FA. All other hematological disorders which manifest signs and symptoms of FA and all the congenital structural disorders which are associated with FA should be ruled out.
Paroxysmal nocturnal hemoglobinuria (PNH): patients present with anemia, hemoglobin in urine, jaundice, and increased risk of thrombosis. PNH occurs due to the mutation of a gene (PIGA) which encodes for the protein glycosylphosphatidylinositol (GPI), in hematopoietic progenitor cells. This leads to the activation of complement system which further causes nocturnal hemolysis.5

Acquired aplastic anemia: numerous toxicogenic agents lead to acquired hematopoietic stem cell destruction in the bone marrow. Hypocellularity of bone marrow without chromosome breakage, when chromosomes are subjected to stress cytogenetic test, is seen in aplastic anemia. However, pancytopenia along with chromosome fragility is the principal feature of FA.5,30,31

Diamond Blackfan anemia: it is a pure red cell aplasia which typically presents as a defect in erythropoiesis. Patients present with macrocytic-normochromic anemia, normal platelets, normal WBCs, and low reticulocytes.32

Shwachman-Diamond syndrome (SDS): impaired hematopoiesis, pancreatic insufficiency, and predisposition to leukemia are cardinal features of SDS. It is primarily bone marrow aplasia in which neutropenia predominates with the neutrophil count less than 1,500 x 10^9/L.33

Bloom syndrome: patients present with photosensitivity, short stature, learning difficulties, telangiectatic erythema, malignancy, immunodeficiency, type 2 diabetes mellitus, and lupus-like skin lesions on the face. There is severe pre- and postnatal growth retardation.34,35

Congenital amegakaryocytic thrombocytopenia: it predominantly affects platelets and leads to the absence of megakaryocytes. The patient presents with bleeding from day 1 of life or in the first month. There is severe thrombocytopenia which can later progress into leukemia or aplastic anemia.36

### Evaluation of Fanconi Anemia Patients

It was first propounded by Schroeder et al that chromosomal breakage study should be used as a cellular marker for FA patients. But later, many studies revealed that the hypersensitivity of FA cells to clastogens proves to be an authentic marker for the diagnosis of the disease. It is concluded from different studies that the average age of diagnosis of FA is 7 years. It is delayed till the time bone marrow failure sets in. However, prenatal diagnosis and increased awareness have led to an early diagnosis of the disease which further prevent severe complications.3,37

Patients showing signs and symptoms of FA should be thoroughly evaluated. A complete blood count which reveals a reduced number of RBC, WBC, platelet is pancytopenia. There could be an increased fetal hemoglobin level due to high stress. Macrocytosis is depicted by increased mean corpuscular volume. Bone marrow biopsy and investigation show hypocellularity, absence of erythroid, myeloid, megakaryocytic cell lines, and bone marrow aplasia along with fatty marrow.

Chromosomal breakage study/stress cytogenetics should be done in patients with severe pancytopenia. Severe pancytopenia is when hemoglobin is less than 10 g/dL, reticulocyte count is less than 40,000/m, absolute neutrophil count is less than 100/mL, platelet count is less than 50,000/mL, and bone marrow cellularity is less than 25%. This should be done with DNA cross-linking agents (clastogens) such as MMC and DEB. These agents will increase the chromatid’s gap, breaks, rearrangement, or reduplication. For those patients who have had hematopoietic stem cell transplants and patients who test negative for chromosomal breakage test with blood, cultured fibroblasts should be used.1,5 Prenatal diagnosis of FA has a vital role to play. It should be known to the clinicians

| Differential diagnosis | Salient features |
|------------------------|------------------|
| PNH                    | Patients present with anemia, hemoglobin in urine, jaundice, and an increased risk of thrombosis. PNH occurs due to the mutation of a gene (PIGA) which encodes for the protein GPI, in hematopoietic progenitor cells. This leads to the activation of complement system which further causes nocturnal haemolysis.5 |
| Acquired aplastic anemia| Numerous toxicogenic agents lead to acquired hematopoietic stem cell destruction in the bone marrow. Hypocellularity of bone marrow without chromosome breakage, when chromosomes are subjected to stress cytogenetic test is seen in aplastic anemia. However, pancytopenia along with chromosome fragility is the principal feature of FA.5,30,31 |
| Diamond Blackfan anemia| It is a pure red cell aplasia which typically presents as a defect in erythropoiesis. Patients present with macrocytic-normochromic anemia, normal platelets, normal WBCs, and low reticulocytes.32 |
| SDS                    | Impaired hematopoiesis, pancreatic insufficiency, and predisposition to leukemia are cardinal features of SDS. It is primarily bone marrow aplasia in which neutropenia predominates with the neutrophil count less than 1,500 x 10^9/L.33 |
| Bloom syndrome         | Patients present with photosensitivity, short stature, learning difficulties, telangiectatic erythema, malignancy, immunodeficiency, type 2 diabetes mellitus, and lupus-like skin lesions on the face. There is severe pre- and postnatal growth retardation.34,35 |
| Congenital amegakaryocytic thrombocytopenia | It predominantly affects platelets and leads to the absence of megakaryocytes. Presents with bleeding from day 1 of life or in the first month. There is severe thrombocytopenia which can later progress into leukemia or aplastic anemia.36 |
that amniocentesis, chorionic villous sampling, and umbilical cord blood sampling can be used for chromosomal breakage study.\(^1\,3,8-40\) Prenatal diagnosis of FA has played an important role in developing a model for umbilical cord blood transplant which can serve as a substitute to bone marrow transplant in the treatment of various hematological disorders.\(^3,41\)

Cell cycle analysis by flowcytometry can be used as an alternative diagnostic tool in differentiating between FA and non-FA I individuals. It is evident that the duration of G2M phase is prolonged in FA cells as compared with non-FA cells. Gene sequencing is recommended in those patients who test positive for chromosomal breakage tests.\(^42\)

**Conclusion**

Well-timed diagnosis is of utmost importance in any genetic disease. Genetic counseling plays an important role in explaining the patients’ relatives the course of the disease and also to prevent the occurrence of the same disease in the next child. The clinician must be well acquainted with the fact that timely diagnosis and genetic counseling are essential to start the therapy for the patient as early as possible. Parents of the child should be counseled regarding the availability of prenatal diagnosis and preimplantation genetic diagnosis. This will further help in reducing the burden of genetic diseases in society.

**Funding**

None.

**Conflict of Interest**

None declared.

**References**

1. Auerbach AD. Fanconi anemia and its diagnosis. Mutat Res 2009; 668(1–2):4–10
2. García-de-Teresa B, Rodríguez A, Frías S. Chromosome instability in Fanconi anemia: from breaks to phenotypic consequences. Genes (Basel) 2020;11(12):1528
3. Rosenberg PS, Tamary H, Alter BP. How high are carrier frequencies of rare recessive syndromes? Contemporary estimates for Fanconi anemia in the United States and Israel. Am J Med Genet A 2011;155A(08):1877–1883
4. D’Andrea AD, Grompe M. The Fanconi anemia/BRCA pathway. Nat Rev Cancer 2003;3(01):23–34
5. Bhandari J, Thada PK, Puckett Y. Fanconi anemia. [Updated 2022 Jan 2]. In: StatPearls [Internet]. Treasure Island, FL: StatPearls Publishing; 2022. Accessed June 02, 2022 at: https://www.ncbi.nlm.nih.gov/books/NBK559133/
6. Grompe M, D’Andrea A. Fanconi anemia and DNA repair. Hum Mol Genet 2001;10(20):2253–2259
7. Meetei AR, Levitus M, Xue Y, et al. X-linked inheritance of Fanconi anemia complementation group B. Nat Genet 2004;36(11):1219–1224
8. Wang AT, Kim T, Wagner JE, et al. A dominant mutation in human RAD51 reveals its function in DNA interstrand crosslink repair independent of homologous recombination. Mol Cell 2015;59(03):478–490
9. Bagby G. Recent advances in understanding hematopoiesis in Fanconi anemia. F1000 Res 2018;7:105
10. Chandrasekharappa SC, Lach FP, Kimber DC, et al; NISC Comparative Sequencing Program. Massively parallel sequencing, aCGH, and RNA-Seq technologies provide a comprehensive molecular diagnosis of Fanconi anemia. Blood 2013;121(22):e138–e148
11. Kee Y, D’Andrea AD. Expanded roles of the Fanconi anemia pathway in preserving genomic stability. Genes Dev 2010;24(16):1680–1694
12. George M, Solanki A, Chavan N, et al. A comprehensive molecular study identified 12 complementation groups with 56 novel FANC gene variants in Indian Fanconi anemia subjects. Hum Mutat 2021;42(12):1648–1665
13. Adachi D, Oda T, Yagasaki H, et al. Heterogeneous activation of the Fanconi anemia pathway by patient-derived FANCA mutants. Hum Mol Genet 2002;11(25):3125–3134
14. Yamashita T, Barber DL, Zhu Y, Wu N, D’Andrea AD. The Fanconi anemia polypeptide FACC is localized to the cytoplasm. Proc Natl Acad Sci U S A 1994;91(17):7975–7979
15. Hoatlin ME, Christianson TA, Keeble WW, et al. The Fanconi anemia group C gene product is located in both the nucleus and cytoplasm of human cells. Blood 1998;91(04):1418–1425
16. McMahon LW, Walsh CE, Lambert MW. Human alpha spectrin II and the Fanconi anemia proteins FANCA and FANCC interact to form a nuclear complex. J Biol Chem 1999;274(46):32904–32908
17. Yamashita T, Kupfer GM, Naf D, et al. The Fanconi anemia pathway requires FAA phosphorylation and FAA/FAC nuclear accumulation. Proc Natl Acad Sci U S A 1998;95(22):13085–13090
18. Li R, Murray AW. Feedback control of mitosis in budding yeast. Cell 1991;66(03):519–531
19. Hoyt MA, Toret L, Roberts BT. S. cerevisiae genes required for cell cycle arrest in response to loss of microtubule function. Cell 1991;66(03):507–517
20. Lara-González P, Westhorpe FG, Taylor SS. The spindle assembly checkpoint. Curr Biol 2012;22(22):R986–R980
21. Musacchio A, Salmon ED. The spindle-assembly checkpoint in space and time. Nat Rev Mol Cell Biol 2007;8(05):379–393
22. Glanz A, Fraser FC. Spectrum of anomalies in Fanconi anemia. J Med Genet 1982;19(06):412–416
23. Ogilvie P, Hofmann UB, Bröcker EB, Hamm H. [Skin manifestations of Fanconi anemia]. Hautarzt 2002;53(04):253–257
24. Yamashita T, Nakahata T. Current knowledge on the pathophysiology of Fanconi anemia: from genes to phenotypes. Int J Hematol 2001;74(01):33–41
25. Alter BP. Fanconi’s anemia and malignancies. Am J Hematol 1996;53(02):99–110
26. Young NS, Alter BP. Clinical features of Fanconi’s anemia. In: Young NS, Alter BP, eds. Aplastic anemia, Acquired and Inherited. Philadelphia, PA: Saunders; 1994:275–309, 20
27. Faivre L, Guardiola P, Lewis C, et al; European Fanconi Anemia Research Group. Association of complementation group and mutation type with clinical outcome in Fanconi anemia. Blood 2000;96(13):4064–4070
28. Wajnrajch MP, Gertner JM, Huma Z, et al. Evaluation of growth and hormonal status in patients referred to the International Fanconia Anemia Registry. Pediatrics 2001;107(04):744–754
29. Hou JW, Wang TR. Differentiation of Fanconi anemia from aplastic anemia by chromosomal breakage test. Zhonghua Min Guo Xia Er Ke Yi Xue Hui Za Zhi 1997;38(02):121–126
30. Talmoudi F, Kilani O, Ayed W, et al. Differentiation of Fanconi anemia from aplastic anemia using mitomycin C test in Tunisia. C R Biol 2013;336(01):29–33
31. Gadhiya K, Willis C. Diamond Blackfan Anemia. [Updated 2022 Jan 31]. In: StatPearls [Internet]. Treasure Island, FL: StatPearls Publishing; 2022 Jan. Accessed June 02, 2022 at: https://www.ncbi.nlm.nih.gov/books/NBK545302/?report=classic
33 Burroughs L, Woolfrey A, Shimamura A. Shwachman-Diamond syndrome: a review of the clinical presentation, molecular pathogenesis, diagnosis, and treatment. Hematol Oncol Clin North Am 2009;23(02):233–248
34 Vekaria R, Bhatt R, Saravanan P, de Boer RC. Bloom's syndrome in an Indian man in the UK. BMJ Case Rep 2016;2016:bcr2015212297
35 Hafsi W, Badri T, Rice AS. Bloom Syndrome. [Updated 2021 Jul 6]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing. HHS Vulnerability Disclosure. Accessed June 02, 2022 at: https://www.hhs.gov/vulnerability-disclosure-policy/index.html
36 Al-Qahtani FS. Congenital amegakaryocytic thrombocytopenia: a brief review of the literature. Clin Med Insights Pathol 2010;3:25–30
37 Schroeder TM, Anschütz F, Knopp A. Spontaneous chromosome aberrations in familial panmyelopathy. Humangenetik 1964;1(02):194–196
38 Auerbach AD, Sagi M, Adler B. Fanconi anemia: prenatal diagnosis in 30 fetuses at risk. Pediatrics 1985;76(05):794–800
39 Auerbach AD, Min Z, Ghosh R, et al. Clastogen-induced chromosomal breakage as a marker for first trimester prenatal diagnosis of Fanconi anemia. Hum Genet 1986;73(01):86–88
40 Auerbach AD. Diagnosis of Fanconi anemia by diepoxybutane analysis. In: Dracopoli NC, Haines JL, Korf BR, Moir DR, Morton CC, Seidman CE, Seidman JG, Smith DR, eds. Current Protocols Human Genetics. Supplement. Vol. 37. Hoboken, NJ: John Wiley & Sons, Inc; 2003:8.7.1–8.7.15
41 Auerbach AD, Liu Q, Ghosh R, Pollack MS, Douglas GW, Broxmeyer HE. Prenatal identification of potential donors for umbilical cord blood transplantation for Fanconi anemia. Transfusion 1990;30(08):682–687
42 Seyschab H, Friedl R, Sun Y, et al. Comparative evaluation of diepoxybutane sensitivity and cell cycle blockage in the diagnosis of Fanconi anemia. Blood 1995;85(08):2233–2237